How Chronic Inflammation Shapes Breast Cancer Risk and Growth

Inflammation is usually something people notice: a sprained ankle, a sore throat, redness that fades in a few days. But a slower, quieter version can persist in the body for years without any visible sign. Research increasingly ties this long-running form of inflammation to cancer, including breast cancer. It does not announce itself. Instead, immune signals stay switched on at a low level, gradually reshaping the tissue around them.

Inflammation as an Enabling Condition for Cancer

Cancer biologists now treat chronic inflammation as one of the conditions that makes cancer development possible, not simply a side effect of a tumor that already exists. Influential work describing the core biological traits shared across cancers, including an analysis by Douglas Hanahan and Robert Weinberg, lists inflammation among the features that help tumors get started and keep growing. Related research describes inflammation as something that can promote genetic damage, encourage new blood vessel growth, and help abnormal cells escape signals that would normally trigger their elimination. This does not mean inflammation causes cancer by itself. It means that when inflammation becomes chronic, it changes the environment tissue sits in, making that environment more hospitable to cells that would otherwise be cleared away.

Obesity, Breast Fat, and Crown-Like Structures

One of the clearest examples of this plays out in breast fat tissue, especially after menopause. Fat tissue is not just storage. It is active, hormone-producing tissue, and in obesity, fat cells can die faster than the body clears them away. When that happens, immune cells gather around the dying fat cells in a ring-shaped pattern researchers call a crown-like structure. These clusters are a visible marker of localized inflammation inside the breast itself. Research led by Andrew Dannenberg's group found these structures more often in breast tissue from obese women with breast cancer, alongside a more broadly inflamed tissue environment. This matters particularly after menopause, when fat tissue becomes the body's main source of estrogen, a hormone that can fuel the growth of certain breast cancers.

From Inflamed Fat to Local Estrogen Production

That hormone connection runs through an enzyme called aromatase, which converts other hormones into estrogen inside breast tissue. Inflamed fat containing crown-like structures produces higher levels of signaling molecules that push aromatase activity upward. The result is more estrogen made locally, right where breast tissue sits, rather than relying only on estrogen circulating from elsewhere in the body. For breast cancers that depend on estrogen to grow, known as hormone receptor-positive cancers, this local boost could plausibly support tumor growth. The evidence for this pathway comes mainly from tissue studies in obese women, so it describes a mechanism that appears biologically active rather than a fully proven driver of disease in every patient.

Immune Cells Living Inside the Tumor

Inflammation's influence does not stop at the fat surrounding a tumor. Breast tumors are embedded in what researchers call a tumor microenvironment, the mix of blood vessels, signaling molecules, and immune cells surrounding cancer cells that shapes how those cells behave. Among the immune cells found there, tumor-associated macrophages stand out. Macrophages normally help clear damaged cells and debris, but inside a tumor they can be reprogrammed to support growth instead of fighting it. Research examining the mix of immune cells across breast tumors, associated with David DeNardo and colleagues, found that this immune composition predicted patient survival and affected how tumors responded to chemotherapy. The immune environment around a tumor, in other words, is not a passive bystander. It actively participates in how the disease progresses and how well treatment works.

What Blood Tests Can and Cannot Tell Us

Because inflammation can be measured in blood, researchers have asked whether simple blood markers predict breast cancer risk or outcomes. C-reactive protein, a substance the liver releases during inflammation, and interleukin-6, a signaling molecule immune cells use to communicate, have both been studied this way. Elevated levels of these markers have been associated with reduced survival among breast cancer patients, and C-reactive protein has been examined across many cancer types as a marker tied to diagnosis and prognosis. These associations are useful for understanding biology, but they are not established tools for predicting an individual person's breast cancer risk. Inflammation markers rise for many reasons unrelated to cancer, which limits how specific they can be on their own.

Inflammatory Breast Cancer Is a Separate, More Urgent Diagnosis

It is worth separating all of this from inflammatory breast cancer itself, a distinct and rare diagnosis that should not be confused with the general inflammatory processes described above. It does not usually present as a lump. Instead, cancer cells block lymphatic vessels in the skin of the breast, causing it to become red, swollen, and warm, sometimes within weeks. It is biologically aggressive and tends to spread faster than more common breast cancer subtypes. Its name reflects the breast's visibly inflamed appearance, not the underlying chronic inflammation discussed elsewhere in this article. The two ideas share a word, but they should not be collapsed into one.

Could Anti-Inflammatory Drugs Lower Risk?

If chronic inflammation contributes to cancer development, an obvious question follows: could drugs that reduce inflammation also reduce cancer risk? Aspirin and other anti-inflammatory drugs, sometimes called NSAIDs, work partly by blocking enzymes involved in inflammatory signaling. An analysis combining data from multiple randomized trials found that daily aspirin use was associated with a reduced long-term risk of dying from cancer, with some relevance to breast cancer, though results varied across cancer types and were not uniformly strong. Separately, researchers have begun exploring whether directly treating obesity-related fat tissue inflammation, rather than relying on general anti-inflammatory drugs, could become a strategy for lowering breast cancer risk. That work remains investigational. Aspirin and similar drugs also carry real risks, including bleeding, so decisions about using them for cancer-related reasons should involve a physician rather than independent use.

Where the Evidence Leaves Us

Taken together, the research paints chronic inflammation as a genuine contributor to breast cancer biology, acting through several connected channels: fat tissue inflammation and local estrogen production, immune cells living inside tumors, and circulating markers that track with outcomes. None of these channels works alone, and none of them turns inflammation into a single, deterministic cause of breast cancer. Obesity remains just one risk factor among many, and inflammatory markers are clues rather than diagnostic tools. What the field still needs is clearer evidence on whether directly targeting inflammation changes outcomes, rather than simply correlating with them. For now, the relationship between inflammation and breast cancer is best understood as an active, evolving area of research rather than a settled story with a simple fix.